Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Firdous Ghori"'
Publikováno v:
Clinical Case Reports, Vol 11, Iss 5, Pp n/a-n/a (2023)
Abstract Chronic myeloid leukemia (CML) is a myeloproliferative disorder due to translocation between chromosomes (9, 22), known as the “Philadelphia chromosome.” In 2016, the World health organization (WHO) introduced a new clinical entity of de
Externí odkaz:
https://doaj.org/article/bf192578f19543cf8e36f77de4ee2f20
Autor:
Afra M. Elhassan, Arwa Alsaud, Mohamed A. Yassin, Mahmood Aldapt, Lubna Riaz, Firdous Ghori, Aiman Bin Ahmad, Mohammad Abdulla
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 2, Pp 675-679 (2020)
Essential thrombocythemia (ET) is one of the myeloproliferative neoplasms, characterized by persistent thrombocytosis, platelets >450,000/μL, and evident clonal abnormalities like JAK2 V617F, MPL, CALR mutation and not fulfilling WHO criteria for MD
Externí odkaz:
https://doaj.org/article/3ee40ee54b0342999968839e5b90fdc9
Autor:
Mohamed A Yassin, Rola Ghasoub, Ashraf Soliman, Omar Ismail, Abdulqadir J Nashwan, Awni Alshurafa, Firdous Ghori, Deena Sideeg, Anas Hamad, Radwa Hussein, Randa Al-Okka, Prem Chandra, Aya Alasmar
Publikováno v:
Cureus.
Eltrombopag olamine (ELT) is a synthetic nonpeptide with a low molecular weight that has been investigated in various phase-3 studies and shown to be efficacious at a typical dose of 50 mg. Varied ethnic groups have reported different responses to EL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::539c637acc2207d4bdec1adce66000af
https://doi.org/10.7759/cureus.25701
https://doi.org/10.7759/cureus.25701
Autor:
Mohamed A. Yassin, Dina Sameh Soliman, Abulrahman Arabi, Alia M. Amer, Firdous Ghori, Ahmed Elyas
Polycythemia Vera (PV) is a clonal myeloproliferative disease characterized by an erythroid dominant trilineage proliferation of hematopoietic precursor cells. Acute coronary syndrome is known to occur in patients with PV. However, there are very rar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a19fdeff9162019a7f8c57dbedbe82ae
https://doi.org/10.21203/rs.3.rs-420929/v1
https://doi.org/10.21203/rs.3.rs-420929/v1
Autor:
Anas Hamad, Firdous Ghori, Rola Ghasoub, Omer Ismail, Mohamed A. Yassin, Abdulqadir J. Nashwan, Prem Chandra, Aya Alasmar, Deena Sideeg
Publikováno v:
Blood. 136:8-9
Introduction: The thrombopoietin receptor agonists (TPO-RA) such as eltrombopag (ELT) have, in recent years, changed immune thrombocytopenia (ITP) treatment, showing that there is both increased platelet destruction and suboptimal platelet production
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa9d5355a37cb0c9589ac5db8d46e297
https://doi.org/10.1182/blood-2020-134421
https://doi.org/10.1182/blood-2020-134421
Autor:
Radwa M Hussein, Prem Chandra, Abdulqadir J. Nashwan, Aya Alasmar, Deena Sideeg, Anas Hamad, Mohamed A. Yassin, Rola Ghasoub, Omer Ismail, Firdous Ghori, Randa Al Okka, Ashraf Soliman
Publikováno v:
Blood. 136:7-8
Background: Thrombopoietin receptor agonists stimulate platelet production . Eltrombopag olamine (ELT) is alow molecular weight, synthetic nonpeptide agent thathas been studied in multiple phase 3 trials and proved efficacy at a standard dose of 50 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da14baa85b8111421ac86788f5f08456
https://doi.org/10.1182/blood-2020-134416
https://doi.org/10.1182/blood-2020-134416